Characteristics of individuals with MBL and patients with CLL
| Characteristic . | No. (%) . | P* . | |
|---|---|---|---|
| Group A (training) . | Group B (validation) . | ||
| Individuals with MBL (n = 111) | |||
| No. of patients | 63 | 48 | |
| ZAP70 expression | |||
| Positive | 10 (16) | 9 (19) | .99 |
| Negative | 42 (67) | 38 (79) | |
| No data | 11 (17) | 1 (2) | |
| IgHV mutation status | |||
| Mutated | 46 (73) | 29 (60) | .38 |
| Unmutated | 15 (24) | 14 (29) | |
| No data | 2 (3) | 5 (10) | |
| FISH results | |||
| Negative | 17 (27) | 14 (29) | .99 |
| 13q deletion | 21 (33) | 14 (29) | |
| Trisomy 12 | 13 (21) | 9 (19) | |
| 11q deletion | 2 (3) | 2 (4) | |
| 17p deletion | 1 (2) | 0 (0) | |
| Other | 1 (2) | 1 (2) | |
| No data | 8 (13) | 8 (17) | |
| Median time to treatment (mo) | Not reached | Not reached | .02 |
| 5 y treated | 14% | 28% | |
| 10 y treated | 19% | 28% | |
| Patients with CLL (n = 93) | |||
| No. of patients | 70 | 23 | |
| Rai stage | |||
| 0-II | 60 (86) | 19 (83) | .74 |
| III-IV | 10 (14) | 4 (17) | |
| ZAP70 expression | |||
| Positive | 20 (29) | 7 (30) | .99 |
| Negative | 32 (46) | 11 (48) | |
| No data | 18 (26) | 5 (22) | |
| IgHV mutation status | |||
| Mutated | 41 (59) | 15 (65) | .62 |
| Unmutated | 26 (37) | 7 (30) | |
| No data | 3 (4) | 1 (4) | |
| FISH results | |||
| Negative | 9 (13) | 5 (22) | .054 |
| 13q deletion | 29 (41) | 14 (61) | |
| Trisomy 12 | 18 (26) | 1 (4) | |
| 11q deletion | 1 (1) | 1 (4) | |
| 17p deletion | 6 (9) | 0 (0) | |
| Other | 1 (1) | 0 (0) | |
| No data | 6 (9) | 2 (9) | |
| Median time to treatment (mo) | 78.4 | Not reached | .08 |
| 5 y treated | 41% | 23% | |
| 10 y treated | 74% | 34% | |
| Characteristic . | No. (%) . | P* . | |
|---|---|---|---|
| Group A (training) . | Group B (validation) . | ||
| Individuals with MBL (n = 111) | |||
| No. of patients | 63 | 48 | |
| ZAP70 expression | |||
| Positive | 10 (16) | 9 (19) | .99 |
| Negative | 42 (67) | 38 (79) | |
| No data | 11 (17) | 1 (2) | |
| IgHV mutation status | |||
| Mutated | 46 (73) | 29 (60) | .38 |
| Unmutated | 15 (24) | 14 (29) | |
| No data | 2 (3) | 5 (10) | |
| FISH results | |||
| Negative | 17 (27) | 14 (29) | .99 |
| 13q deletion | 21 (33) | 14 (29) | |
| Trisomy 12 | 13 (21) | 9 (19) | |
| 11q deletion | 2 (3) | 2 (4) | |
| 17p deletion | 1 (2) | 0 (0) | |
| Other | 1 (2) | 1 (2) | |
| No data | 8 (13) | 8 (17) | |
| Median time to treatment (mo) | Not reached | Not reached | .02 |
| 5 y treated | 14% | 28% | |
| 10 y treated | 19% | 28% | |
| Patients with CLL (n = 93) | |||
| No. of patients | 70 | 23 | |
| Rai stage | |||
| 0-II | 60 (86) | 19 (83) | .74 |
| III-IV | 10 (14) | 4 (17) | |
| ZAP70 expression | |||
| Positive | 20 (29) | 7 (30) | .99 |
| Negative | 32 (46) | 11 (48) | |
| No data | 18 (26) | 5 (22) | |
| IgHV mutation status | |||
| Mutated | 41 (59) | 15 (65) | .62 |
| Unmutated | 26 (37) | 7 (30) | |
| No data | 3 (4) | 1 (4) | |
| FISH results | |||
| Negative | 9 (13) | 5 (22) | .054 |
| 13q deletion | 29 (41) | 14 (61) | |
| Trisomy 12 | 18 (26) | 1 (4) | |
| 11q deletion | 1 (1) | 1 (4) | |
| 17p deletion | 6 (9) | 0 (0) | |
| Other | 1 (1) | 0 (0) | |
| No data | 6 (9) | 2 (9) | |
| Median time to treatment (mo) | 78.4 | Not reached | .08 |
| 5 y treated | 41% | 23% | |
| 10 y treated | 74% | 34% | |
For categorical data (Rai stage/ZAP70 expression/IgHV mutation status/FISH results), the Fisher exact test was used to calculate P values; for median time to treatment as continuous variable, the Mann-Whitney-Wilcoxon test was used.